This document discusses diabetes and cardiovascular disease risk factors and complications. It summarizes that obesity predisposes individuals to both diabetes and cardiovascular disease. It then outlines various circadian and molecular pathways involved in metabolic regulation and the potential role of nuclear receptors and transcription factors like Rev-erbα and RORα. Finally, it describes several European research consortia studying diabetes and cardiovascular disease, as well as the creation of the European Genomics Institute of Diabetes, which aims to conduct basic, clinical, and translational research towards developing new diabetes treatments through collaborations between academia and the pharmaceutical industry.